REG - Asimilar Group PLC - Update re. Suspension

AsimilarAnnouncement

31/07/2020 12:15

RNS Number : 7940U
  
Asimilar Group PLC
  
31 July 2020
  
 

 
 
31 July 2020
 
 
Asimilar Group plc
 
('Asimilar' or the 'Company')
 
Update re. Suspension
 
Following the announcement on 14 February 2020 regarding the possible investment in Sentiance NV, the Company's shares were suspended from trading on AIM with immediate effect, as the transaction would be classified as a reverse takeover in accordance with Rule 14 of the AIM Rules for Companies ("AIM Rules"). Ordinarily under the AIM Rules, the Company has six months from the date of suspension to publish an admission document setting out, inter alia, details of the proposed transaction or confirm these discussions have ceased.  If neither of these outcomes is achieved, trading in the Company's shares on AIM will be cancelled.
 
Due to market impact of Covid-19, the Company has been granted an extension from six to twelve months from 14 February 2020 for publishing such an admission document or to confirm discussions concerning the proposed investment have ceased.
 
Asimilar is continuing to work with its Nominated Adviser and other professional advisers on its admission document in relation to the proposals announced on 4 and 12 March 2020, although there is no guarantee that a formal agreement will be reached.
 
Further announcements will be made in due course.  
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
 
-Ends-
Contacts




Asimilar Group plc


 




John Taylor, Non-Executive Chairman


via Buchanan




 


 




Cairn Financial Advisers LLP


 




Sandy Jamieson / Liam Murray


Tel: +44 20 7213 0880




 


 




Peterhouse Capital Limited


 




Duncan Vasey / Lucy Williams


Tel: + 44 20 7220 9797




 


 




Buchanan Communications Limited


 




Richard Oldworth / Chris Lane


Tel: +44 (0) 20 7466 5000




 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
UPDRBMBTMTBJBMM